Umeclidinium in patients with COPD: a randomised, placebo-controlled study Source: Eur Respir J 2014; 43: 72-81 Year: 2004
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Late-breaking abstract: Inhaled pan-selectin antagonist bimosiamose in COPD: A double-blind, randomized, placebo-controlled phase II study Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011
Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical Trials: "Aerosolized Lancovutide (Moli1901)" and "Oral Sildenafil" Year: 2009
Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis Source: Eur Respir J 2014; 43: 1114-1123 Year: 2014
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021 Year: 2022
Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007
Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021
Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009
Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012
A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis Source: Eur Respir J 2015; 46: 1021-1032 Year: 2015
A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018
Randomized double-blind placebo-controlled trial of azithromycin in lung transplantation: first results Source: Annual Congress 2008 - New insights and treatment options for bronchiolitis obliterans syndrome after lung transplantation Year: 2008
A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008
Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011